Antibody + Drug + Third Party, Antibody + siRNAASO + Third Party
GLP 1 at Scale
Digital Quality Management Systems as Strategic Enablers of Patient-Centric Manufacturing Excellence
The Increasing Importance of Manufacturability in API Development
AI in Pharmaceutical Manufacturing Operations
EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharmacovigilance in the GLP-1 Era: Safety Surveillance Challenges for Obesity Medicines and Real-World Use
The rapid uptake of GLP therapies is pushing pharmacovigilance beyond traditional slower models built for smaller and more controlled treatment popula...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
Forgotten Biology: The Missing Link Behind Trial Outcomes
Clinical trials are often described as the science of uncertainty and that uncertainty is expected It is how evidence is built However not all uncertainty is scientific In many cases it arises when the biological context of an intervention is not carried through into the study population
-
Techno Trends
Terns Pharmaceuticals Secures FDA Breakthrough Therapy Designation for TERN-701 in CML
Terns Pharmaceuticals Inc has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration for TERN a novel oral allosteric BCRABL inhibitor
-
Projects
PCI Pharma Services Expands Global Manufacturing Network with $1B+ Investment in San Diego
PCI Pharma Services has announced an investment programme exceeding billion across its US and European operations to strengthen sterile fillfinish and advanced drug delivery capabilities
-
Research Insights
Interpretable multivariate survival models: Improving predictions for conversion from mild cognitive impairment to Alzheimer’s disease via data fusion and machine learning
Accurately predicting which individuals with mild cognitive impairment MCI will progress to Alzheimers disease AD can improve patient care This study examines the role of quantitative MRI qMRI cognitive evaluations
-
White Papers
Accelerating In-Vitro Antibody Discovery with Artificial Intelligence
Antibodies have transformed modern medicine reshaping treatment paradigms across autoimmune disorders oncology and infectious diseases As one of the most versatile and successful therapeutic modalities
TOP ARTICLES
-
1
Innovations in Antibody-Drug Conjugates: A Deep Dive into Pharma's Future
Kate Williamson
Antibody-Drug Conjugates (ADCs) for cancer therapy, are truly a hybrid of both monoclonal antibodies as well as cytotoxic drugs. In this article, we shall focus on the future developments of the ADC t...
-
2
FDA Regulatory Updates and Their Impact on Drug Approval Processes
Kate Williamson
This article will elaborate on the transformations of the restructured regulatory changes on the FDA drug approval processes, clinical development, compliance strategies, and accelerated pathways. It...
-
3
Embracing AI to Revolutionize Drug Safety: A Call for Modernizing Pharmacovigilance Practices
Pramod Kumar
Pharmacovigilance is vital for protecting patients, but traditional approaches fail to address diverse populations and real-world complexities. This article highlights how AI, particularly LLMs and Ge...
-
4
Biosimilars in the U.S.: Unraveling Market Dynamics and Winning B2B Collaboration Strategies
Kate Williamson
This B2B guide delves into the dynamic landscape of biosimilars in the U.S., offering insights into market dynamics and successful collaboration strategies. From understanding regulatory challenges to...
-
5
Stem Cell Technology: The Future of Drug Discovery and Regenerative Medicine
Kate Williamson
Drug discovery together with regenerative medicine undergoes revolutionary changes because stem cell technology allows appropriate drug testing and tissue reconstruction and customized therapeutic app...
press releasesRead more...
PharmaLogic and Ratio Therapeutics Expand Manufacturing Collaboration to Support Clinical Development of [Ac-225]RTX-2358
PharmaLogic Holdings Corp a leading contract development and manufacturing organization CDMO specialized in radiopharmaceuticals today announced an expansion of its manufacturing partnership with Ratio Therapeutics
AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
AbbVie NYSE ABBV today announced that the European Commission EC has authorized an expanded label for VENCLYXTO venetoclax to include use in combination with acalabrutinib with or without obinutuzumab
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
Pfizer Inc NYSE PFE and Innovent Biologics Inc HK today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of promising new breakthrough
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
Vanda Pharmaceuticals Inc Vanda Nasdaq VNDA today announced that Japans Ministry of Health Labour and Welfare MHLW has granted orphan drug designation to imsidolimab a highaffinity humanized immunoglobulin
Events Read more...
01 - 02
Jun 2026Future Pharma 2026
Renaissance Seaport District, Boston, MA, USA
02 - 04
Jun 2026CPHI Americas 2026
Pennsylvania Convention Center, Philadelphia, USA
04 - 05
Jun 2026Pharmac South 2026
Chennai Trade Centre, Nandambakkam, India
04 - 06
Jun 2026Global Bioprocessing Summit & Exhibition 2026
Berlin, Germany
09 - 11
Jun 20265th World ADC Summit South Korea
COEX Magok Lewest, 143 Magokjungang-ro, Gangseo-gu, Seoul, South Korea
09 - 11
Jun 2026World TPD & Induced Proximity Summit South Korea
COEX Magok Lewest, 143 Magokjungang-ro, Gangseo-gu, Seoul, South Korea
09 - 11
Jun 2026World Targeted Therapeutics Summit South Korea
COEX Magok Lewest, 143 Magokjungang-ro, Gangseo-gu, Seoul, South Korea
09 - 10
Jun 2026ChemE Show 2026
George R. Brown Convention Center, Houston, Texas, USA
LATEST NEWSRead more...
Pfizer and Innovent Biologics Form Global Oncology Partnership to Advance Cancer Drug Development
Pfizer and Innovent Biologics have entered into a global strategic licensing and collaboration agreement to develop earlystage and newly discovered cancer medicines
Lupin Secures U.S. FDA Approval for Generic Colonoscopy Preparation Tablets
Lupin Limited has received approval from the US Food and Drug Administration FDA for its Abbreviated New Drug Application ANDA for Sodium Sulfate Magnesium Sulfate and Potassium Chloride Tablets g g g
Antengene receives CDE support for Phase III study of ATG-022 in gastric and gastroesophageal junction cancer
Antengene has received approval from the Center for Drug Evaluation CDE of Chinas National Medical Products Administration to begin the pivotal Phase III CLINCH study of ATG for the treatment of CLDNpositive
Kazia Therapeutics expands Phase 1b trial of paxalisib in advanced breast cancer
Kazia Therapeutics has expanded its ongoing Phase b clinical trial of paxalisib in combination with standard treatment therapies for patients with advanced triple negative breast cancer TNBC
Insilico Medicine and Human Longevity Partner to Develop AI Foundation Model for Longevity Science
Insilico Medicine and Human Longevity have announced a multimilliondollar collaboration to codevelop what the companies describe as the industrys first largescale artificial intelligence AI foundation model focused on human longevity science
TD2 Oncology and Panome Bio Expand Partnership for Translational Oncology Research
Panome Bio a multiomics contract research organisation CRO and CLIAcertified laboratory has expanded its strategic partnership with TD Oncology an oncologyfocused CRO specialising in preclinical and clinical drug development
